Back to Search Start Over

HOPPSA update: changes in the study protocol of Hysterectomy and OPPortunistic SAlpingectomy, a registry-based randomized controlled trial.

Authors :
Idahl A
Liv P
Darelius A
Collins E
Sundfeldt K
Pålsson M
Strandell A
Source :
Trials [Trials] 2023 Mar 24; Vol. 24 (1), pp. 222. Date of Electronic Publication: 2023 Mar 24.
Publication Year :
2023

Abstract

Background: The HOPPSA trial is a multi-center national registry-based randomized controlled trial to test the safety and effectiveness of performing opportunistic salpingectomy at hysterectomy to reduce the risk of epithelial ovarian cancer (EOC). The study protocol was first published in January 2019 and is available at https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-3083-8 . Here, we report amendments made to the study protocol since commencement of the trial.<br />Changes in Methods and Analysis: The primary outcomes analyses have been changed. (1) Complications will be analyzed using binomial generalized estimating equation (GEE) with log link function, while the unadjusted analyses according to Miettinen and Nurminen will be performed as a sensitivity analysis. (2) Absolute change in Menopause Rating Scale (MRS) will primarily be analyzed using a mixed effects model, adjusted for baseline MRS and center as a random effect. (3) Time to EOC will be analyzed using the mixed effects Cox regression model with center as random effect, while the unadjusted log-rank test will be performed as a sensitivity analysis. The primary outcome Complications will be based solely on the specific assessment in the GynOp quality registry. The Clavien-Dindo classification will be evaluated as a secondary outcome. Furthermore, MRS is also measured three years postoperatively to better pinpoint the onset of menopausal symptoms.<br />Discussion: The changes to the protocol mainly concern the analyses of data. No changes to recruitment, randomization, intervention, or follow-up of primary outcomes have been made. An interim analysis during 2021 concluded that the study should continue until the target sample size is reached.<br />Trial Registration: ClinicalTrials.gov, NCT03045965 . Registered 8 February 2017.<br /> (© 2023. The Author(s).)

Details

Language :
English
ISSN :
1745-6215
Volume :
24
Issue :
1
Database :
MEDLINE
Journal :
Trials
Publication Type :
Academic Journal
Accession number :
36959664
Full Text :
https://doi.org/10.1186/s13063-023-07244-w